CereVasc, Inc. Announces Over-Subscribed $85 Million Series C Financing to Advance its Novel eShunt® System for the Treatment of Normal Pressure Hydrocephalus

Rhea-AI Summary

CereVasc completed an over-subscribed $85 million Series C financing led by Piper Sandler Merchant Banking (NYSE:PIPR), with participation from JJDC, Medtronic, Bain Capital Life Sciences and Perceptive Xontogeny funds.

Funds support the STRIDE pivotal trial of the eShunt System, PMA work, operational scale-up, commercialization, and board expansion.

Positive

• Over-subscribed $85 million Series C initial closing completed
• Capital to fund STRIDE pivotal trial of the eShunt System in NPH
• Financing supports PMA regulatory work and US commercialization preparation
• Participation from strategic investors including JJDC and Medtronic
• Board expanded with new Lead Independent Director and Audit Committee Chair

Negative

• None.

News Market Reaction – PIPR

+1.89%

+1.89% Session close to close

In the Jun 4 session, PIPR gained 1.89%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement underscores Piper Sandler’s merchant banking and healthcare franchise, leading an ...

Analysis

This announcement underscores Piper Sandler’s merchant banking and healthcare franchise, leading an $85 million Series C for CereVasc to advance its eShunt System and pivotal STRIDE trial toward a future PMA submission. In recent months, Piper Sandler has also expanded sector teams and product capabilities and reported stronger first-quarter 2026 revenues. Investors may track follow-on mandates from similar clients, overall healthcare deal volume, and how such mandates complement the firm’s broader advisory and capital markets strategy.

Key Figures

Series C financing: $85 million

1 metrics

Series C financing $85 million Initial closing to fund eShunt System development and commercialization prep

Historical Context

5 past events · Latest: Jun 02 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 02	Leadership appointments	Positive	+0.2%	Named new co-heads and enhanced private equity advisory focus.
May 11	Platform expansion	Positive	-1.3%	Launched distressed debt and special asset group in fixed income.
May 01	Earnings and dividend	Positive	-8.9%	Reported Q1 2026 results and increased quarterly dividend to $0.20.
Apr 27	Senior hire	Positive	+1.4%	Added MD to healthcare investment banking team to advise biopharma.
Apr 21	Earnings call notice	Neutral	+0.1%	Announced timing and access details for Q1 2026 earnings call.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Operational expansion and hiring updates often saw modest or mixed next-day reactions, while the recent earnings release drew a notably negative move despite solid results.

Recent Company History

Over the last few months, Piper Sandler has focused on expanding its platform and leadership. It added co-heads for services and industrials investment banking on Jun 2, 2026 and strengthened its healthcare investment banking team on Apr 27, 2026, both tied to small positive price reactions. Platform build-outs, including a distressed debt and special asset group announced on May 11, 2026, saw a negative reaction. First-quarter 2026 earnings on May 1, 2026 with higher revenues and a dividend increase were followed by a sharp selloff, showing that fundamentals and near-term trading have not always aligned.

Key Terms

series c financing, normal pressure hydrocephalus, pivotal trial, randomized, controlled trial, +2 more

6 terms

series c financing financial

"announced it has successfully completed the initial closing of an $85 million Series C financing."

A Series C financing is a late-stage round of private funding companies raise after earlier seed and growth rounds to accelerate expansion, enter new markets, make acquisitions, or prepare for a public listing. For investors, it signals a more developed business with clearer revenue and growth plans—offering a chance to buy into a company closer to maturity but with higher upfront valuation and potential dilution, so it’s a trade-off between reduced early-stage risk and higher price.

normal pressure hydrocephalus medical

"ongoing STRIDE pivotal trial in patients with Normal Pressure Hydrocephalus (NPH)."

A condition in which excess fluid builds up in the brain’s cavities, gently raising pressure and squeezing nearby tissue; think of it like a slightly overfilled water balloon pressing on delicate components. It can cause walking difficulty, slowed thinking and bladder problems, and is important to investors because it drives demand for diagnostic tests, surgical devices and drug research—areas that can generate steady medical spending, clinical trials and revenue for healthcare companies.

pivotal trial medical

"STRIDE is a prospective, multi-center, randomized, controlled trial designed to evaluate..."

A pivotal trial is a key test of a new medicine or treatment to see if it works and is safe enough to be approved by health authorities. It's like a final exam for a new product, and passing it is essential for bringing the treatment to the public.

randomized, controlled trial medical

"STRIDE is a prospective, multi-center, randomized, controlled trial designed to evaluate..."

A randomized, controlled trial assigns participants by chance into two or more groups—one receiving the treatment being tested and the other receiving a standard treatment or placebo—so outcomes can be fairly compared. Think of it like flipping a coin to place people into different teams to avoid bias; investors use results from these trials as strong evidence about a drug or medical device’s real benefits and risks, which can materially affect regulatory approval, market potential, and company value.

ventriculo-peritoneal (vp) shunt medical

"compared to the current standard of care, the ventriculo-peritoneal (VP) shunt, and is intended..."

A ventriculo-peritoneal (VP) shunt is a small implanted tube system that diverts excess fluid from the brain’s ventricles to the abdominal cavity, relieving pressure much like a plumbing pipe reroutes an overflowing sink. Investors care because hospitals’ use of these devices, how safe and durable they are, and whether they get regulatory approval and reimbursement directly affect sales, legal risk, and long-term market demand for manufacturers and suppliers.

premarket approval (pma) regulatory

"intended to support a future Premarket Approval (PMA) submission to the FDA."

Premarket Approval (PMA) is the strict regulatory review process used by the U.S. authority for high-risk medical devices to prove they are safe and effective before they can be sold. For investors, a granted PMA is like receiving a key to a locked market: it can open exclusive sales opportunities, reduce near-term competition, and justify higher valuations, while also signaling that the company has cleared a costly, time-consuming hurdle.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Financing led by Piper Sandler Merchant Banking, with participation from new investors Johnson & Johnson Innovation – JJDC, Inc., Johnson & Johnson's corporate venture capital arm, and Medtronic
  
  
• Participation by existing investors, including Bain Capital Life Sciences and Perceptive Xontogeny Venture Funds
  
  
• Proceeds will support the conclusion of the STRIDE pivotal trial, continued operational scale-up, advancement of regulatory work toward a future Premarket Approval (PMA) submission to the FDA, and preparations for US commercialization
  
  
• Board strengthened with addition of Kevin Conroy as Lead Independent Director, Christopher Geyen as Chair of the Audit Committee, and Tom Schnettler representing Series C investors

BOSTON, June 4, 2026 /PRNewswire/ -- CereVasc, Inc., a clinical-stage medical device company developing novel, minimally invasive treatments for neurological diseases, today announced it has successfully completed the initial closing of an $85 million Series C financing. Piper Sandler Merchant Banking led the financing with participation from Johnson & Johnson Innovation – JJDC, Inc., Johnson & Johnson's corporate venture capital arm, and Medtronic, along with existing investors Bain Capital Life Sciences and Perceptive Xontogeny Venture Funds.

Proceeds from the financing will fund continued clinical and regulatory development of CereVasc's eShunt System, including the ongoing STRIDE pivotal trial in patients with Normal Pressure Hydrocephalus (NPH). STRIDE is a prospective, multi-center, randomized, controlled trial designed to evaluate the safety and effectiveness of the eShunt System compared to the current standard of care, the ventriculo-peritoneal (VP) shunt, and is intended to support a future Premarket Approval (PMA) submission to the FDA. The company will also advance organizational growth and operational scale-up as it moves toward commercialization.

In conjunction with the closing, the company strengthened the Board of Directors with the addition of Kevin Conroy as Lead Independent Director, Christopher Geyen as an independent director and Chair of the Audit Committee, and Tom Schnettler of Piper Sandler Merchant Banking representing the new Series C investors.

"This Series C financing is a meaningful milestone for CereVasc, and more importantly, for the patients who are living with conditions for which current treatment options remain inadequate," said Dan Levangie, Chairman and Chief Executive Officer of CereVasc. "This funding supports the next critical phase for the eShunt System, including PMA submission and preparation for commercial launch — accelerating our path toward a minimally invasive surgery that we believe has the potential to meaningfully improve patient outcomes and quality of life. We are delighted to welcome a slate of new investors and directors whose experience and conviction will help guide CereVasc through this next phase of growth, and we remain deeply grateful for the continued support of our existing partners."

About CereVasc, Inc.
Located in Massachusetts' healthcare hub, CereVasc, Inc. is a clinical-stage medical device company focused on developing novel, minimally invasive treatments for patients with neurological diseases. Its initial product, the eShunt System, employs an innovative percutaneous transvenous-transdural approach to the central nervous system and is intended to enable the first minimally invasive treatment for communicating hydrocephalus (CH). The patented eShunt System includes an endovascularly implantable cerebrospinal fluid shunt and delivery components designed to treat CH without invasive surgery. For additional information, please visit our website at www.cerevasc.com.

About Piper Sandler Merchant Banking
Piper Sandler Merchant Banking (PSMB) is the growth equity investment arm of Piper Sandler Companies (NYSE: PIPR). The PSMB team strives to partner with founders and management teams of high potential businesses that can benefit by leveraging Piper Sandler's knowledge, experience, capital and relationships to build market leading enterprises. PSMB provides investment advisory services through the affiliated registered investment adviser, PSC Capital Partners LLC. Learn more about Piper Sandler Merchant Banking.

The eShunt System is an investigational device and has not been approved by FDA or any other regulatory agency for commercial sale. Its safety and effectiveness have not yet been fully established.

Contacts

Media Contact:
Tiffany Weil
CereVasc, Inc.
tiffanyweil@cerevasc.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/cerevasc-inc-announces-over-subscribed-85-million-series-c-financing-to-advance-its-novel-eshunt-system-for-the-treatment-of-normal-pressure-hydrocephalus-302791507.html

SOURCE CereVasc, Inc.

FAQ

What did CereVasc announce on June 4, 2026 that may interest PIPR investors?

CereVasc announced an over-subscribed $85 million Series C financing. According to CereVasc, the round was led by Piper Sandler Merchant Banking and will fund clinical, regulatory and commercialization efforts for its minimally invasive eShunt System for Normal Pressure Hydrocephalus.

How will CereVasc use the $85 million Series C financing for its eShunt System (PIPR)?

CereVasc plans to use the $85 million Series C proceeds to advance its eShunt System. According to CereVasc, funds support the STRIDE pivotal trial, regulatory work toward future PMA submission, organizational growth, operational scale-up and preparations for US commercialization activities.

Which investors joined CereVasc's $85 million Series C round connected to Piper Sandler (PIPR)?

The Series C was led by Piper Sandler Merchant Banking with several strategic investors. According to CereVasc, participants included Johnson & Johnson Innovation – JJDC, Medtronic, and existing investors Bain Capital Life Sciences and Perceptive Xontogeny Venture Funds.

What is the STRIDE pivotal trial funded by CereVasc's Series C financing (PIPR)?

STRIDE is a prospective, multi-center, randomized, controlled pivotal trial of the eShunt System. According to CereVasc, it evaluates safety and effectiveness versus ventriculo-peritoneal shunts in Normal Pressure Hydrocephalus and is intended to support a future PMA submission to the FDA.

How does CereVasc's Series C financing advance its FDA PMA strategy for the eShunt System (PIPR)?

The Series C financing will fund key steps toward a future PMA submission. According to CereVasc, proceeds support completion of the STRIDE pivotal trial and broader regulatory development activities needed to move the eShunt System toward potential FDA approval and commercialization.

What board of director changes accompanied CereVasc's $85 million Series C financing (PIPR)?

CereVasc expanded its board alongside the Series C closing. According to CereVasc, Kevin Conroy joined as Lead Independent Director, Christopher Geyen as independent director and Audit Committee Chair, and Tom Schnettler of Piper Sandler Merchant Banking joined representing the new Series C investors.